

## **Investor Webinar: Phase 3 Update and Probability of Success**

---

**Paradigm Biopharmaceuticals Ltd (ASX: PAR) (“Paradigm” or “the Company”)**, a late-stage biopharmaceutical company developing novel treatments for musculoskeletal diseases, is pleased to invite investors to an upcoming webinar to be held on:

**Date:** Thursday 31 July 2025

**Time:** 9:00am AEST

**Presenters:** Paul Rennie (Managing Director) and Dr Donna Skerrett (Chief Medical Officer)

**Registration Link:**

[https://us02web.zoom.us/webinar/register/WN\\_WY8ir3NpTUqJQXnRexhhjw](https://us02web.zoom.us/webinar/register/WN_WY8ir3NpTUqJQXnRexhhjw)

The webinar will provide a comprehensive update on Paradigm's global phase 3 clinical trial (PARA\_OA\_012) of injectable pentosan polysulfate sodium (iPPS) for knee osteoarthritis, with a particular focus on the trial's optimised design, regulatory alignment, and high probability of success (PoS) based on extensive prior data and FDA engagement.

Investors are invited to send questions prior to the webinar to:

[investorrelations@paradigmbiopharma.com](mailto:investorrelations@paradigmbiopharma.com).

After registering, you will receive a confirmation email about joining the webinar. A recording will be available shortly after the conclusion of the session on the Paradigm website.

A copy of the presentation for the webinar will be available prior to the webinar via ASX and the paradigm website.

<https://paradigmbiopharma.com/performance-progress/#announcements>.

### **About Paradigm Biopharmaceuticals**

Paradigm Biopharmaceuticals Ltd. (ASX: PAR) is a late-stage drug development company driven by a purpose to improve patients' health and quality of life by discovering, developing, and delivering pharmaceutical therapies. Paradigm's current focus is developing iPPS for the treatment of diseases where inflammation plays a major pathogenic role, indicating a need for the anti-inflammatory and tissue regenerative properties of PPS, such as in osteoarthritis (phase 3).

Authorised for release by the Paradigm Board of Directors.

To learn more please visit: [www.paradigmbiopharma.com](http://www.paradigmbiopharma.com)

**FOR FURTHER INFORMATION PLEASE CONTACT:**

Simon White

Director of Investor Relations

Tel: +61 404 216 467

Paradigm Biopharmaceuticals Ltd

ABN: 94 169 346 963

Level 15, 500 Collins St, Melbourne, VIC, 3000, AUSTRALIA

Email: [investorrelations@paradigmbiopharma.com](mailto:investorrelations@paradigmbiopharma.com)